Aurinia Pharmaceuticals Inc. focuses on autoimmune diseases with unmet needs and delivers therapies to help patients.

Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. | 26,452 followers on LinkedIn. We pursue promising science to address some of the toughest challenges in autoimmune disease. 
 
Community guidelines:
1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 
 
2.

Ray Federico

CEO, BalkanTrials

Luc Opsomer, MD, MBA

VP, Associate General Counsel, Data Privacy Officer | Senior Legal Advisor| Business Partner| | DEI Leader & Champion| Life Sciences |…

Eman Ahmed-Fakhry

Sarah Beyersdorf

Today, we announced our Q3 financial results and company updates. Details can be found here: https://lnkd.in/gtp-GHXP

November is #NativeAmericanHeritageMonth , and we recognize the unique health challenges faced by Native American communities, including a higher prevalence of lupus nephritis (Lupus Foundation of America, 2023). Among Native Americans, LN occurs at twice the rate seen in other populations, highlighting the need for greater awareness and access to care. At Aurinia, we are committed to advocating for equitable healthcare and supporting efforts to improve outcomes through education, research, and community partnerships. Read more about our resources here: https://lnkd.in/gHBi5nNZ

On November 7, we will be sharing our Q3 2024 financial results and company updates. Details can be found here: https://lnkd.in/gP2wb8z3

We're excited to announce our presence at the American Society of Nephrology Conference, October 24-27, where we’ll be sharing new data demonstrating our commitment to advancing care for #lupusnephritis . Learn more: https://lnkd.in/gN5S_z_b

Hispanic women are twice as likely to develop lupus nephritis compared to white women (Lupus Foundation of America, 2023). This #HispanicHeritageMonth , we’re highlighting the need for increased awareness and support for #lupus and #lupusnephritis research among diverse populations. Learn more about our resources here: https://lnkd.in/egCmCqZM

Today, we’re excited to share that our lupus nephritis (LN) therapy has now been approved in Japan. This approval marks a significant step forward in helping even more people with LN achieve better long-term kidney outcomes. Read more: https://lnkd.in/gS4vw3en

We strongly believe our teammates who carry out our values in their everyday work are our greatest asset at Aurinia. Throughout the year, we’ll be spotlighting the winners of values-based, peer-driven ONE Aurinia Awards, celebrating the hard work and dedication of those who exemplify our four core values. Stay tuned for our upcoming winner announcements! Learn more about our mission, vision, and values: https://lnkd.in/eXGiwNDz

We’re pleased to announce our upcoming presence at the Cantor Fitzgerald Investor Conference, September 17-19. Learn more: https://lnkd.in/g3kD2wEa

Aurinia has announced Board restructuring. Details can be found here: https://lnkd.in/gq9fpUh4

Lupus nephritis disproportionately affects Hispanic women. Ahead of #HispanicHeritageMonth , we are zooming in on two impactful events to support and educate the #lupus and #lupusnephritis communities: On September 14th, CLUES is hosting the annual Fiesta Latina, a free, family-friendly community festival celebrating different aspects of Latino heritage, in St. Paul, Minnesota. We will be providing Spanish language materials for all participants. Learn more: https://lnkd.in/gNtqGVb7 On September 21st, the Lupus Society of Illinois , Northwestern Medicine and the National Kidney Foundation of Illinois are hosting an educational event on #lupusnephritis . Learn more: https://lnkd.in/gj_3_TjS Through advocacy, we’re committed to raising awareness and building a supportive network for those affected by lupus and lupus nephritis. #TogetherWeShine

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 5:33 AM	6458ae9e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 5:33 AM	ce8f5f52
crunchbase trigger	general	Nov 27, 2024 12:50 PM	205c06cd
crunchbase profile	general
li profile	general	Nov 12, 2024 5:33 AM	859e5228
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 5:33 AM	a5bc4495
news basic	general	Nov 12, 2024 5:33 AM	fbf2dd93
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AURINIAPHARMA

Aurinia Pharmaceuticals Inc.

Last Close

8.77

22/11 21:00

Market Cap

786.60M

Beta: -

Volume Today

1.56M

Avg: -